Status:

UNKNOWN

Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients

Lead Sponsor:

Gruppo Italiano Malattie EMatologiche dell'Adulto

Conditions:

CLL

B-cell

Eligibility:

All Genders

18+ years

Brief Summary

This is a non interventional study to evaluate the efficacy and safety of Chlorambucil plus Rituximab as firstline therapy in elderly and/or unfit patients affected by B-cell Chronic Lymphocytic Leuke...

Detailed Description

Illness: treatment overview Chronic lymphocytic leukemia (B-CLL) is the most prevalent adult leukemia among western countries (6.7% Non-Hodgkin Lymphomas- NHL). The incidence rate is 2-6 cases per 100...

Eligibility Criteria

Inclusion

  • Have a diagnosis of B-CLL or Small Lymphocytic Lymphoma (SLL) according to the World Health Organisation (WHO) classification 2008;
  • Previously untreated B-CLL requiring therapy according to the NCI criteria (Hallek M et al, Blood 2008 (Appendix G) undergone to first line of therapy with Chl-R;
  • All patients included in the study must have started treatment by December 2011;
  • Age ≥ 65 years or unfit pts ≥ 18 years old with a CIRS score ≥7 (Appendix E);
  • Eastern Cooperative Oncology Group Performance Status Grade of 0-2 (Appendix B) ;
  • Life expectancy \> 6 months;
  • Signed written informed consent according to ICH/EU/GCP and national local law.

Exclusion

  • Patients who have received prior therapy: chemotherapy and/or immunotherapy, stem cell transplantation, investigational drugs administered to treat B-CLL before Chl-R;
  • Transformation of B-CLL to aggressive lymphomas (Richter's Syndrome);
  • One or more individual organ/system impairment score of 4 as assessed by CIRS definition;
  • HIV infection;
  • Active, uncontrolled HCV and/or HBV infections or liver cirrhosis;
  • Patients who started Chl-R after December 2011.

Key Trial Info

Start Date :

October 1 2013

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 1 2018

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT01862445

Start Date

October 1 2013

End Date

May 1 2018

Last Update

March 22 2018

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno

Ascoli Piceno, Italy

2

UOC Ematologia Ospedale " Monsignor Raffaele Dimiccoli"

Barletta, Italy

3

Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia

Catanzaro, Italy

4

Sezione di Ematologia e Fisiopatologia delle Emostasi

Ferrara, Italy